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Objective. The efficacy and safety of abatacept in
patients with juvenile idiopathic arthritis (JIA) who expe-
rienced an inadequate response to disease-modifying anti-
rheumatic drugs were previously established in a phase
III study that included a 4-month open-label lead-in peri-
od, a 6-month double-blind withdrawal period, and a
long-term extension (LTE) phase. The aim of this study
was to present the safety, efficacy, and patient-reported
outcomes of abatacept treatment (10 mg/kg every 4 weeks)
during the LTE phase, for up to 7 years of followup.
Methods. Patients enrolled in the phase III trial
could enter the open-label LTE phase if they had not
achieved a response to treatment at month 4 or if they
had received abatacept or placebo during the double-
blind period.
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3Richard Mouy, MD: Hôpital Necker-Enfants Malades, AP-HP, Paris,
France; 4Eliana Paz, MD: Instituto de Salud del Nino, Lima, Peru;
5Nadina Rubio-Perez, MD: Hospital Universitario Dr. J. E. Gonzalez,
Monterrey, Mexico; 6Clovis A. Silva, MD, PhD: Children’s Institute,
Hospital das Clinicas, and Faculdade de Medicina da Universidade de
S~ao Paulo, S~ao Paulo, Brazil; 7Carlos Abud-Mendoza, MD: Hospital
Central Dr. Ignacio Morones Prieto y Facultad de Medicina and Uni-
versidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico;
8Ruben Burgos-Vargas, MD: Hospital General de Mexico and Univer-
sidad Nacional Autonoma de Mexico, Mexico City, Mexico; 9Valeria
Gerloni, MD: Istituto Ortopedico Gaetano Pini, Milan, Italy; 10Jose
A. Melo-Gomes, MD: Instituto Portugues de Reumatologia, Lisbon,
Portugal; 11Claudia Saad-Magalhaes, MD, PhD: Universidade Estad-
ual Paulista, Botucatu, Brazil; 12J. Chavez-Corrales, MD: Hospital
Nacional Edgardo Rebagliati, Lima, Peru; 13Christian Huemer, MD:
Landeskrankenhaus Bregenz, Bregenz, Austria; 14Alan Kivitz, MD,
CPI: Altoona Arthritis and Osteoporosis Center, Duncansville,
Pennsylvania; 15Francisco J. Blanco, MD: Hospital Universitario A
Coru~na, A Coru~na, Spain; 16Ivan Foeldvari, MD: Hamburger Zen-
trum f€ur Kinder und Jugendrheumatologie, Hamburg, Germany;
17Michael Hofer, MD: Centre Multisite Romand de Rhumatologie
Pediatrique, Lausanne, Switzerland; 18Hans-Iko Huppertz, MD:
Professor Hess Kinderklinik, Bremen, Germany; 19Chantal Job
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Results. One hundred fifty-three (80.5%) of 190
patients entered the LTE phase, and 69 patients (36.3%)
completed it. The overall incidence rate (events per 100
patient-years) of adverse events decreased during the LTE
phase (433.61 events during the short-term phase [com-
bined lead-in and double-blind periods] versus 132.39
events during the LTE phase). Similar results were
observed for serious adverse events (6.82 versus 5.60), seri-
ous infections (1.13 versus 1.72), malignancies (1.12 versus
0), and autoimmune events (2.26 versus 1.18). American
College of Rheumatology (ACR) Pediatric 30 (Pedi 30)
responses, Pedi 70 responses, and clinically inactive dis-
ease status were maintained throughout the LTE phase in
patients who continued to receive therapy. Improvements
in the Child Health Questionnaire physical and psychoso-
cial summary scores were maintained over time.
Conclusion. Long-term abatacept treatment for up
to 7 years was associated with consistent safety, sustained
efficacy, and quality-of-life benefits in patients with JIA.
Juvenile idiopathic arthritis (JIA) is one of the
most common chronic diseases of childhood and the most
prevalent of the pediatric rheumatic illnesses (1–3). The
outcome for patients with JIA can be described in terms
of persistent synovitis and joint damage, with diminished
daily function and quality of life (QOL); nearly 50% of
children with JIA will have recurrent or persistent disease
and will enter adulthood with active arthritis and ongoing
joint destruction (1). Importantly, the associated disability
and pain can have a negative impact on physical and psy-
chological health (4,5). Furthermore, JIA is associated
with a significant burden on caregivers (6).
Treatment with biologic agents has led to im-
proved clinical outcomes in terms of reductions in disease
activity and inflammation, with concurrent improvements
in function and health-related QOL (HRQOL), as evalu-
ated using patient-reported outcomes (PROs) (7–15).
The chronic nature and childhood onset of JIA mean
that many patients will continue to receive therapy with
biologic agents for extended periods of time. Further-
more, the possible increased risk of certain adverse
events (AEs) associated with biologic agent treatment
must be monitored. As such, it is important to evaluate
the safety and tolerability, and the sustainability of clini-
cal efficacy and QOL benefits, of long-term treatment.
Abatacept is a biologic agent that selectively mod-
ulates T cell costimulation. It is currently approved in the
US and the European Union for the treatment of moder-
ately to severely active polyarticular JIA in patients
ages 6 years or older (16). Abatacept selectively modu-
lates the CD28:CD80/86 costimulatory signal required
for full T cell activation (17). The efficacy and safety of
abatacept in patients with JIA who had an inadequate
response to at least 1 disease-modifying antirheumatic
drug (DMARD), including anti–tumor necrosis factor
(anti-TNF) antagonists, were previously examined in a
phase III study, which included a 4-month open-label
lead-in phase and a 6-month double-blind period, fol-
lowed by a long-term extension (LTE) phase (12).
The efficacy of abatacept was confirmed during the
6-month double-blind period, during which placebo-treated
patients were 3 times more likely to experience a flare com-
pared with patients who continued to receive abatacept.
Furthermore, the frequency of AEs did not differ between
the abatacept and placebo groups. Improvements in QOL
and PROs, such as pain, activity limitation, and sleep, were
also observed in patients treated with abatacept compared
with those treated with placebo (18). Safety and efficacy
results from $21 months of the LTE period demonstrated
that long-term abatacept treatment continued to be well tol-
erated and was associated with clinically significant and
durable efficacy, including in patients who were not
responders (according to the American College of Rheu-
matology [ACR] Pediatric 30 [Pedi 30] criteria for improve-
ment) by month 4 of therapy (19). The aim of this study
was to assess the long-term safety, clinical efficacy, QOL,
and PROs in patients exposed to abatacept for ;30 addi-
tional months, for up to 7 years of total followup.
PATIENTS AND METHODS
Patient population and study design. The phase III
study (ClinicalTrials.gov identifier NCT00095173) included
patients with JIA ages 6–17 years from 43 pediatric rheumatol-
ogy centers in Europe, Latin America, and the US belonging
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to the Pediatric Rheumatology Collaborative Study Group or
the Paediatric Rheumatology International Trials Organisa-
tion (20). To be eligible, patients were required to have had an
inadequate response or intolerance to at least 1 DMARD
(including TNF-blocking agents), active disease at the time of
enrollment (at least 2 joints with active arthritis and 2 joints
with limited range of motion), and a history of at least 5 joints
with active arthritis (swollen joints or joints with a limited
range of motion and pain or tenderness).
The study design was previously described (19). Briefly,
the study consisted of a 4-month open-label lead-in phase, during
which all patients received open-label abatacept, followed by a 6-
month double-blind withdrawal phase, during which patients
who had achieved an ACR Pedi 30 response at the end of the 4-
month lead-in period were assigned randomly to receive either
abatacept or placebo. These patients could then enter the open-
label LTE phase. Patients were also eligible to enter the LTE
directly if they completed the open-label lead-in phase without
achieving an ACR Pedi 30 response or if they had experienced a
flare during the double-blind withdrawal period while receiving
abatacept or placebo. The study ended after the last patient com-
pleted 5 years of followup during the LTE phase.
During the open-label LTE phase, all patients received
abatacept by intravenous infusion at a dose of 10 mg/kg, up to a
maximum dose of 1,000 mg. The dosages of oral corticosteroids
(maximum 10 mg/day prednisone equivalent or 0.2 mg/kg/day,
whichever was less) and methotrexate (#30 mg/m2 body surface
area/week up to a maximum allowed dosage of 40 mg/m2 body
surface area/week if required) could be adjusted during the LTE
phase. The use of nonsteroidal antiinflammatory drugs or anal-
gesics and the addition of hydroxychloroquine, sulfasalazine, or
azathioprine were permitted during the LTE phase. Up to 2
intraarticular injections of corticosteroids per year were permit-
ted, and any injected joint was considered “active” at all subse-
quent visits.
This study was conducted in accordance with Good Clin-
ical Practice and with the ethics principles of the Declaration of
Helsinki. The protocol, amendments, and patient informed con-
sent form received approval by the relevant institutional review
board or ethics committee at each participating site.
Assessments performed. The primary objective of the
LTE period was to assess the safety of continued long-term aba-
tacept treatment. Safety data were recorded at each study visit up
to a maximum of 7 years of treatment, representing the maxi-
mum exposure time in the study. Acute infusion-related events
were defined as those reported within 1 hour of the start of infu-
sion. The definitions of a serious adverse event (SAE) included a
fatal or life-threatening AE, an AE requiring hospitalization or
prolonged hospitalization, an AE resulting in persistent or signifi-
cant disability or incapacity, cancer, a congenital anomaly/birth
defect, overdose, development of drug dependency or drug
abuse, or an important medical event.
The secondary objective was to assess the efficacy of
abatacept treatment. Clinical efficacy and QOL evaluations
were performed quarterly during the LTE phase and collected
until day 1,765 (;5.5 years). Improvements in the signs and
symptoms of JIA were evaluated in terms of the proportions of
patients achieving ACR Pedi 30, Pedi 50, Pedi 70, and Pedi 90
responses (21) or clinically inactive disease status (as deter-
mined using the study-specific definition of no joints with active
disease, a physician’s global assessment disease activity score of
#10 [range 0–100], and an erythrocyte sedimentation rate
[ESR] of #20 mm/hour). The ACR Pedi responses were calcu-
lated by comparing the differences between the last visit and
the baseline visit at the start of the phase III study, prior to the
first abatacept infusion.
In this study, ACR Pedi responses were evaluated using
the ESR as the laboratory measure of acute inflammation in the
core set of measures of improvement and response in JIA (21).
The Child Health Questionnaire (CHQ) was used to evaluate
physical, emotional, and social aspects of HRQOL in the patients;
raw scores were transformed to a scale of 0–100, with higher
scores indicating better QOL. Physical summary and psychosocial
summary scores of the CHQ were normalized using data from
healthy children in the US; mean 6 SD scores of 50 6 10 were
considered within the normal range for healthy children (22,23).
Disability was assessed using the Childhood Health
Assessment Questionnaire (C-HAQ) disability index, which is a
component of the criteria for an ACR Pedi response (23). Pain
was assessed using the parent’s global assessment score. Parents
were asked how much pain due to illness their child had experi-
enced in the past week; responses were measured using an
anchored 100-mm visual analog scale, where 0 indicates no pain
and 100 indicates very severe pain. The impact of JIA on sleep
quality was evaluated using the Children’s Sleep Habits Ques-
tionnaire (CSHQ) (24,25); total scores range from 0 to 100,
with higher scores indicating more sleep problems. The CSHQ
consists of 33 items, assessing the following 8 domains of sleep
behavior: bedtime resistance, sleep onset delay, sleep duration,
sleep anxiety, night awakenings, parasomnias, sleep-disordered
breathing, and daytime sleepiness. The questionnaire has been
validated in children ages 4–10 years, with a total score of $41
identifying children with sleep disorders.
Participation in daily activities for both patients and
parents was assessed using a questionnaire in which parents
were asked the following 3 questions (with responses scored as
the number of days during the past 30 days): On how many
days did your child’s JIA keep him/her from attending school
(excluding vacation/holidays)? On how many days did your
child’s JIA keep you from doing your usual activities? On how
many days did you pay for child care for your son/daughter
with JIA in order for you to engage in your usual activities?
To evaluate immunogenicity, serum samples were
obtained from the patients prior to dosing (day 1) and on the
scheduled assessment days and assayed for the induction of
abatacept-specific antibodies, using enzyme-linked immuno-
sorbent assays to detect antibodies to the whole abatacept
molecule (CTLA-4 and immunoglobulin portion) or the
CTLA-4 region alone (CTLA-4 “tip”).
Statistical analysis. The analyses were based on data
derived from the 153 patients who entered the LTE phase and
received at least 1 infusion of abatacept; the data for these
patients were pooled and represent the open-label lead-in,
double-blind randomized, and open-label LTE periods. Safety
data are presented as incidence rates (IRs) with 95% confi-
dence intervals (95% CIs), which were calculated as the num-
ber of events per 100 patient-years of exposure (number of
patients with event/exposure [person-years] 3 100). Patient-
years of exposure were censored at the time of the first occur-
rence of an AE. Safety analyses were based on data obtained
up to 56 days after administration of the last abatacept dose.
Clinical efficacy and QOL analyses were based on data
derived from patients for whom data were available at each
time point (as-observed) and are presented for 3 subgroups:
OUTCOME OF LONG-TERM ABATACEPT TREATMENT IN JIA 2761
patients who received abatacept during the 6-month double-
blind withdrawal period (double-blind abatacept group),
patients who received placebo during the 6-month double-
blind withdrawal period (double-blind placebo group), and
patients who did not achieve an ACR Pedi 30 response during
the initial 4-month open-label lead-in period and who entered
the LTE phase directly (initial nonresponder group). ACR
Pedi responses over time during the LTE phase were com-
bined from day 1 of the LTE for the double-blind abatacept
and double-blind placebo groups, because all patients were
receiving abatacept at this stage. No formal statistical testing
was performed during the LTE phase.
RESULTS
Patient disposition. Of the 190 patients enrolled
in the phase III trial, 153 (80.5%) entered the LTE
phase. One hundred seventeen patients (58 in the abata-
cept group and 59 in the placebo group) entered the
LTE phase following completion of the double-blind
withdrawal period or after developing disease flare dur-
ing this period, and 36 patients who completed the lead-
in phase but did not achieve an ACR Pedi 30 response
entered the LTE phase directly. Of the 37 children who
did not enter the LTE phase, 20 discontinued participa-
tion during the open-label lead-in period (lack of efficacy,
n 5 17; AEs, n 5 1; lost to followup, n 5 1; other, n 5 1);
11 patients who were nonresponders during the lead-in
period did not enter the LTE phase and instead left the
study (the reasons were not collected); 1 patient who
was a responder during the lead-in period left the study
before the start of the double-blind period (withdrawal
Figure 1. Disposition of the patients with juvenile idiopathic arthritis during the long-term extension (LTE) phase. * 5 One patient withdrew
consent and left the study during the double-blind (DB) treatment period. † 5 The reasons for discontinuation were not reported.
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of consent); and 5 patients left the study during the
double-blind period (in the abatacept arm, lack of effi-
cacy [n 5 1] and withdrawal of consent [n 5 1]; in the
placebo arm, lack of efficacy [n 5 3]). Of the 153
patients who entered the LTE phase, 69 completed it,
and 84 patients discontinued treatment, including 24
who discontinued due to lack of efficacy and 6 who dis-
continued because of AEs (see Figure 1 for a complete
listing of all discontinuations).
The demographic and clinical characteristics at
baseline of the patients who entered the LTE phase are
shown in Table 1. The mean disease duration at baseline
was 4.1 years. Patients had an average of 16.0 joints with
active disease and significant disability (mean C-HAQ
disability index score of 1.2). The most common JIA cate-
gory was rheumatoid factor–negative polyarthritis (data
not shown). The baseline characteristics of the 153 pa-
tients who entered the LTE phase and the 190 patients
originally enrolled in the phase III trial were comparable.
Exposure. Total exposure to abatacept across the
entire study for patients treated during the LTE phase
was 683.4 patient-years (300.2, 260.1, and 123.3 patient-
years for the double-blind abatacept, double-blind place-
bo, and initial nonresponder groups, respectively). Forty-
three patients were exposed to abatacept for $6 years.
Concomitant medications. At the time of entry
into the LTE phase (day 0), 75.2% of patients (47 [81.0%]
in the double-blind abatacept group, 42 [71.2%] in the
double-blind placebo group, and 26 [72.2%] in the initial
nonresponder group) were receiving methotrexate (the
mean dosage range for the 3 groups was 12.0–13.0 mg/m2
body surface area/week). During the LTE phase, 111
patients (72.5%) were receiving folic acid. A total of 19
patients (12.4%) added a nonbiologic DMARD during
the LTE phase, including 10 patients (17.2%), 4 patients
(6.8%), and 5 patients (13.9%) from the double-blind aba-
tacept, double-blind placebo, and initial nonresponder
groups, respectively.
Azathioprine was initiated in 6 patients (3.9%),
cyclosporine in 2 patients (1.3%), and leflunomide in 4
patients (2.6%). Forty-three patients (28.1%) received
concomitant oral corticosteroids at baseline (the mean
dosage range was 0.13–0.19 mg/kg/day [data for 1 patient
were missing]), and 44 patients (28.8%) received cortico-
steroids at entry into the LTE phase (the mean dosage
range was 0.14–0.21 mg/kg/day [data for 1 patient were
missing]).
A total of 24 patients had missing information on
the route of administration of medication. No patients
received intraarticular corticosteroids at baseline, and 2
patients (1.3%; 1 each in the double-blind abatacept and
placebo groups) received 1 intraarticular corticosteroid
injection within 6 months prior to the start of the LTE
phase. During the LTE period, 63 patients (41.2%)
received oral corticosteroids (the mean dosage range for
those with available data was 0.16–0.23 mg/kg/day), and 23
patients (15.0%) received intraarticular corticosteroid
injections. The mean 6 SD numbers of intraarticular
injections for the double-blind abatacept, double-blind
placebo, and initial nonresponder groups, respectively,
Table 1. Demographic and clinical characteristics at baseline, prior to the first abatacept infusion, of the JIA patients who













Age, years 12.4 6 2.9 12.0 6 2.9 12.7 6 3.1 12.3 6 2.9
Female sex, no. (%) 41 (70.7) 42 (71.2) 23 (63.9) 106 (69.3)
Duration of JIA, years 3.8 6 3.8 4.0 6 3.5 4.8 6 3.9 4.1 6 3.7
No. of joints with active disease 17.8 6 11.2 14.9 6 13.0 14.9 6 13.6 16.0 6 12.5
No. of joints with limited range of motion 16.7 6 12.2 14.6 6 13.9 17.1 6 18.0 16.0 6 14.3
Physician’s global assessment (100-mm VAS) 52.9 6 17.8 51.7 6 20.8 51.4 6 22.4 52.1 6 20.0
Parent’s global assessment (100-mm VAS) 41.8 6 22.9 40.4 6 25.1 44.2 6 25.1 41.8 6 24.1
ESR, mm/hour (normal #20) 31.3 6 27.2 31.5 6 27.7 30.6 6 21.9 31.2 6 26.1
CRP, mg/dl (normal ,0.5) 3.0 6 4.6 2.8 6 3.5 3.8 6 4.9 3.1 6 4.3
C-HAQ disability index score, 0–3 scale 1.3 6 0.7 1.3 6 0.8 1.1 6 0.9 1.2 6 0.8
CHQ physical summary score 30.2 6 13.9 31.0 6 14.9 29.5 6 16.1 30.3 6 14.7
CHQ psychosocial summary score 43.5 6 9.4 44.2 6 10.9 47.0 6 9.9 44.5 6 10.2
CSHQ total score 47.3 6 8.6 45.6 6 6.4 45.6 6 8.1 46.3 6 7.7
Parent’s global assessment of pain (100-mm VAS) 43.8 6 22.8 40.0 6 23.4 46.1 6 23.6 42.9 6 23.2
No. of days of activity missed by parent or
caregiver per month
3.8 6 10.3 3.0 6 6.3 3.0 6 6.1 3.3 6 8.0
No. of days of school missed per month 5.6 6 9.5 4.2 6 8.1 2.5 6 4.2 4.3 6 8.0
* Except where indicated otherwise, values are the mean 6 SD. JIA 5 juvenile idiopathic arthritis; LTE 5 long-term exten-
sion; VAS 5 visual analog scale; ESR 5 erythrocyte sedimentation rate; CRP 5 C-reactive protein; C-HAQ 5 Childhood
Health Assessment Questionnaire; CHQ 5 Child Health Questionnaire; CSHQ 5 Children’s Sleep Habits Questionnaire.
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were 0.05 6 0.04, 0.14 6 0.31, and 0.11 6 0.10 per month,
and 0.62 6 0.41, 0.62 6 0.63, and 0.90 6 0.65 per year.
Safety. Safety events reported during the LTE
phase, corresponding to a maximum mean 6 SD total
exposure of 62.1 6 20.9 months, were comparable in the
3 treatment groups (Table 2). One death occurred dur-
ing the LTE phase (motorcycle accident) and was con-
sidered to be unrelated to the study treatment.
The overall IRs of AEs and SAEs reported in the
cumulative study period, corresponding to a mean 6 SD
maximum total exposure of 62.1 6 20.9 months, were
209.11 (95% CI 179.11–242.70) and 5.62 (95% CI 3.92–
7.82) events/100 patient-years of exposure, respectively.
Six patients discontinued participation in the study due to
AEs during the LTE phase, including urticaria and bron-
chospasm (nonserious, considered probably related to the
study treatment), worsening vitiligo (nonserious, consid-
ered unlikely related), skin lesions (nonserious squamous
skin lesions on the head, considered possibly related), tem-
poral lobe epilepsy and multiple sclerosis (serious, consid-
ered possibly related [previously reported; see ref. 19]),
appendicitis (serious, considered possibly related), and
bacterial arthritis (serious, considered probably related).
With the exception of worsening arthritis, no individual
SAE was reported by .2 patients in any group during
the LTE phase. The IR for AEs and SAEs during the
LTE period did not increase relative to the short-term
(combined lead-in and double-blind) treatment period
(Table 3). It is important to note that no patient received
abatacept as isolated therapy.
The overall IR of infections during the cumulative
period was 83.80 (95% CI 70.80–98.49). The IR for most
frequent infections reported were nasopharyngitis (8.85
[95% CI 6.52–11.73]), upper respiratory tract infection (6.81
[95% CI 4.84–9.31]), and influenza (5.58 [95% CI 3.84–
7.84]). The IR for serious infections during the cumulative
abatacept treatment period was 1.65 (95% CI 0.82–2.95).
Serious infections that were considered possibly related to
the study treatment included appendicitis, limb abscess,
impetigo, herpes zoster infection, varicella, and bacterial
arthritis, all of which resolved following treatment. The
most frequently reported serious infections were pyelone-
phritis, bacterial arthritis, and appendicitis (2 patients each).
The IRs for infections and serious infections during the
cumulative period of abatacept treatment did not increase
relative to the short-term treatment period (Table 3).
The overall IR for autoimmune events was 1.18
(95% CI 0.51–2.32). Events during the LTE phase includ-
ed cutaneous vasculitis, psoriasis, vitiligo, uveitis, type 1
diabetes, multiple sclerosis, and Raynaud’s phenomenon
(1 event each). The IR for autoimmune events during the
cumulative abatacept treatment period did not increase
relative to the short-term treatment period (Table 3); in
fact, the incidence decreased, as seen in other LTE studies
of biologic agents in JIA (26,27). One malignancy was pre-
viously reported during the short-term treatment period












Overall AEs 55 (94.8) 54 (91.5) 31 (86.1) 140 (91.5)
Deaths 0 1 (1.7) 0 1 (1.7)†
Discontinuations due to AEs 2 (3.4) 3 (5.1) 1 (2.8) 6 (3.9)
Overall SAEs 9 (15.5) 12 (20.3) 9 (25.0) 30 (19.6)
Discontinuations due to SAEs 1 (1.7) 2 (3.4) 0 3 (2.0)
Most common SAEs‡
Arthritis disease flare 3 (5.2) 0 3 (8.3) 6 (3.9)
Arthralgia 1 (1.7) 1 (1.7) 1 (2.8) 3 (2.0)
Rheumatoid arthritis§ 0 1 (1.7) 1 (2.8) 2 (1.3)
Foot deformity 1 (1.7) 1 (1.7) 0 2 (1.3)
Pyelonephritis 1 (1.7) 0 1 (2.8) 2 (1.3)
Bacterial arthritis 0 1 (1.7) 1 (2.8) 2 (1.3)
Appendicitis 2 (3.4) 0 0 2 (1.3)
Pyrexia 1 (1.7) 1 (1.7) 0 2 (1.3)
Vomiting 1 (1.7) 1 (1.7) 0 2 (1.3)
* The mean 6 SD exposure to abatacept during the long-term extension phase was 48.2 6 24.6 months
(53.2 6 21.0 months, 50.0 6 24.8 months, and 37.4 6 27.0 months in the double-blind abatacept, double-blind
placebo, and initial nonresponder groups, respectively). Values are the number (%). AEs 5 adverse events;
SAEs 5 serious AEs.
† Death attributable to motorcycle accident and considered unrelated to the study treatment.
‡ Defined as those occurring in $1% of the total group.
§ As reported using the Medical Dictionary for Regulatory Activities (version 14.1).
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(leukemia, diagnosed on day 89 of treatment) (12); no
malignant neoplasms were reported during the LTE phase
(Table 3). Seven patients became pregnant while enrolled
in the LTE phase: 1 patient underwent an induced abor-
tion, 4 gave birth to healthy babies, and outcomes for the
remaining 2 patients were not reported. Abatacept was dis-
continued during each of the pregnancies.
Immunogenicity. Two patients developed anti-
bodies to the whole abatacept molecule; in both patients,
this occurred during year 2 of the LTE phase (1 patient
from the double-blind abatacept group, and 1 patient was
an initial nonresponder). Neither of these 2 patients
experienced infusion reactions, and both completed the
LTE phase. Thirty-nine patients exhibited an antibody
response to the CTLA-4 region alone, 31 of whom dem-
onstrated this response during the double-blind period
(22 in the placebo group and 9 in the abatacept group)
and 8 during the LTE phase (initial nonresponders). Of
the 22 patients from the double-blind placebo group,
only 3 continued to demonstrate an antibody response
after being switched back to abatacept therapy during the
LTE period. Two of these patients experienced prespeci-
fied infusion reactions during the LTE phase (1 patient
from the double-blind abatacept group had mild vomiting
[considered by the investigator as being related to treat-
ment], and 1 from the double-blind placebo group experi-
enced mild dizziness and headache [considered by the
investigator as unlikely to be related to treatment]). Nine
patients who developed an antibody response to the
CTLA-4 region discontinued treatment during the LTE
phase (3 due to lack of efficacy [2 initial nonresponders
and 1 from the double-blind placebo group], 2 who were
lost to followup, and 4 due to other reasons).
Clinical efficacy. At the time of entry into the
LTE phase, 49 (84.5%), 46 (79.3%), 32 (55.2%), and 24
(41.4%) of the patients who had received abatacept dur-
ing the double-blind withdrawal period had achieved
ACR Pedi 30, ACR Pedi 50, ACR Pedi 70, and ACR
Pedi 90 responses, respectively, whereas 18 patients
(31.0%) had achieved clinically inactive disease. Owing
to the withdrawal of abatacept for up to 6 months, fewer
patients in the double-blind placebo group (n 5 59) had
achieved ACR Pedi responses at the time they entered
the LTE phase: 40 (67.8%), 31 (52.5%), 18 (30.5%),
and 9 (15.3%) had achieved ACR Pedi 30, Pedi 50, Pedi
70, and Pedi 90 responses, respectively, and 6 (10.2%)
had clinically inactive disease. The mean ACR Pedi
responses for patients in the double-blind placebo group
increased within 6 months of reinstating abatacept ther-
apy during the LTE phase (19), and these responses
were therefore combined with those of patients from the
double-blind abatacept group starting from day 1 of the
LTE phase (Figure 2A) (additional information is avail-
able from the corresponding author). For patients who
did not achieve an ACR Pedi 30 response during the 4-
month lead-in period, and thus entered the LTE phase
directly, ACR Pedi responses gradually increased with
continued long-term abatacept therapy (Figure 2B).
ACR Pedi responses throughout the LTE phase
were also evaluated in a post hoc intent-to-treat (ITT) anal-
ysis based on all 190 patients who had entered the lead-in
phase of the trial, with any patient who discontinued at any
point or had missing data considered a nonresponder. In
this analysis, the proportions of patients achieving an ACR
Pedi 30 response, a Pedi 50 response, a Pedi 70 response, a
Pedi 90 response, and clinically inactive disease status on
day 169 of the LTE phase were as follows: 55.8% (95% CI
48.7–62.9%), 47.4% (95% CI 40.3–54.5%), 35.3% (95%
CI 28.5–42.1%), 22.1% (95% CI 16.2–28.0%), and 17.4%
(95% CI 12.0–22.8%), respectively. By day 1,765, these
responses were achieved by 35.3% (95% CI 28.5–42.1%),
33.7% (95% CI 27.0–40.4%), 27.4% (95% CI 21.0–
33.7%), 20.5% (95% CI 14.8–26.3%), and 16.3% (95% CI
11.1–21.6%) of patients, respectively (Figure 2C).
Patient-reported outcomes. At baseline, the
scores of the patients were lower than those of healthy
children for all health concepts, as evaluated using the
CHQ; following 4 months of abatacept treatment during
Table 3. Summary of adverse events during the short-term and long-term extension phases*
Patients treated during the
short-term phase
(n 5 190)
Patients who entered the
long-term extension phase
(n 5 153)
n IR (95% CI) n IR (95% CI)
AEs 145 433.61 (365.91–510.21) 140 132.39 (111.37–156.22)
SAEs 6 6.82 (2.50–14.84) 30 5.60 (3.78–8.00)
Infections 86 142.40 (113.90–175.87) 120 64.72 (53.66–77.39)
Serious infections 1 1.13 (0.03–6.27) 10 1.72 (0.83–3.16)
Malignancies 1 1.12 (0.03–6.27) 0 0
Autoimmune events 2 2.26 (0.27–8.17) 7 1.18 (0.48–2.44)
* The short-term phase represents the combined lead-in and double-blind periods. IR 5 incidence rate per
100 patient-years of exposure; 95% CI 5 95% confidence interval; AEs 5 adverse events; SAEs 5 serious AEs.
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Figure 2. Proportions of juvenile idiopathic arthritis patients meeting the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50,
Pedi 70, and Pedi 90 criteria for improvement and the proportions achieving an inactive disease status over time. A, Combined group of patients who
received abatacept during the 6-month double-blind withdrawal period and those who received placebo during the 6-month double-blind withdrawal
period. B, Patients who did not achieve an ACR Pedi 30 response during the initial 4-month open-label lead-in period and who entered the long-term
extension (LTE) phase directly. In A and B, data were derived from as-observed analyses based on all patients who entered the open-label LTE. Bars
show the 95% confidence intervals. n 5 number of patients with available data on each visit day. C, Intent-to-treat population. ACR Pedi responses
throughout the LTE phase were also evaluated in a post hoc intent-to-treat analysis based on all 190 patients who had entered the lead-in phase of the
trial, with any patient who discontinued at any point considered a nonresponder. A total of 76 patients remained in the study and had efficacy data
available on day 1,765.
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the open-label lead-in period, substantial improvements
were seen across all health concepts (18). By the start of
the LTE phase, scores for all health concepts in both the
double-blind abatacept and double-blind placebo groups
had reached mean values within 2 SD of the mean for
healthy controls. At the end of the LTE phase, mean
scores for component items on the CHQ were comparable
in all 3 subgroups (double-blind abatacept, double-blind
Figure 3. As-observed and patient- and parent-reported outcomes over time. A and B, Mean Child Health Questionnaire (CHQ) physical summary
(PhS) scores (A) and mean CHQ psychosocial summary (PsS) scores (B). On the x-axis, A, B, and C indicate the 3 study periods. The broken horizon-
tal lines represent a standardized mean score of 50 (and 1 SD below [score of 40]) for the normative population (see ref. 22). C, Parent’s global assess-
ment of pain over time. n 5 the number of patients with available data at each visit day. DB 5 double-blind outcomes during the open-label long-term
extension (LTE) phase. Data were derived from an as-observed analysis based on all patients who entered the LTE phase.
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placebo, and initial nonresponder groups) (additional
information is available from the corresponding author)
(22).
At baseline, the mean physical summary scores
for the patients were below the range for healthy chil-
dren (Figure 3A). Patients who were responders during
the 4-month lead-in phase achieved initial improve-
ments (18) that were sustained with continued long-
term treatment. Initial nonresponders experienced
improvements if they continued to receive treatment
during the open-label LTE phase.
Physical summary scores in the double-blind aba-
tacept, double-blind placebo, and initial nonresponder
groups were within the normal range ($40) in 67.3%,
68.6%, and 43.3% of patients, respectively, on day 169
and in 74.1%, 60.9%, and 66.7%, respectively, on day
1,765. The mean psychosocial summary scores for all 3
treatment groups were within or above the range for
healthy children throughout the study (Figure 3B). Psy-
chosocial summary scores were within the normal range
($40) in 84.6% of patients in the double-blind abata-
cept group, 84.3% of those in the double-blind placebo
group, and 80.0% of those in the initial nonresponder
group on day 169 and in 85.2%, 100.0%, and 91.7%,
respectively, on day 1,765.
During the open-label lead-in period, patients in
all 3 treatment groups had experienced reductions in
pain levels, as assessed using the parent’s global assess-
ment of pain, although reductions in the initial nonres-
ponder group were not as great as those in the double-
blind abatacept and placebo groups, in which patients
had achieved an ACR Pedi 30 response (18). By the
start of the LTE phase, pain scores were further reduced
in the double-blind abatacept group. During the LTE
phase, initial improvements in pain scores were main-
tained over time for patients in all 3 treatment groups
who continued to receive treatment (Figure 3C). Free-
dom from pain (score of 0) was achieved in 20.4% of
patients in the double-blind abatacept group and in
15.7% of those in the placebo group on day 169 and in
17.9% and 16.0% of patients, respectively, on day 1,765.
No initial nonresponders were ranked as being pain-free
at either time point.
Mean values for sleep quality had improved in
patients during the open-label lead-in period and in the
double-blind abatacept group during the 6-month with-
drawal period, as assessed using the CSHQ (18). On day
1,765 of the LTE phase, all groups demonstrated
improvement as demonstrated by mean 6 SD reductions
in the CSHQ total score (26.36 6 1.84, 24.63 6 1.51,
and 23.45 6 1.96 for the double-blind abatacept [n 5 14],
double-blind placebo [n 5 16], and initial nonresponder
[n 5 11] groups, respectively).
Participation in daily activities. Improvements
in activity limitations were seen during the initial study
periods (18) and were maintained with continued abata-
cept treatment, as assessed by the 3 questions regarding
activity participation. On day 1,765 of the LTE phase,
all groups demonstrated mean 6 SD reductions in the
number of missed parent/caregiver activity days per
month (25.52 6 3.14, 22.43 6 0.97, and 23.75 6 2.27
for the double-blind abatacept [n 5 23], double-blind
placebo [n 5 21], and initial nonresponder [n 5 12]
groups, respectively); reductions in the number of school
days missed per month (26.92 6 2.45, 24.68 6 1.88, and
22.08 6 0.87 [n 5 24, n 5 22, and n 5 12], respectively);
and reductions in the number of days of paid care
per month (21.91 6 1.24, 20.09 6 0.09, and 0.17 6 0.17
[n 5 23, n 5 22, and n 5 12], respectively).
DISCUSSION
The LTE phase of this study provided an opportu-
nity to evaluate the safety, clinical efficacy, and patient-
reported QOL in patients with JIA during long-term
treatment with abatacept (up to 7 years). The significant-
ly improved efficacy of abatacept plus methotrexate com-
pared with methotrexate alone in children with JIA who
failed to achieve an adequate response to DMARDs,
including anti-TNF therapy, has already been establi-
shed, with accompanying benefits to HRQOL and consis-
tent safety (12,18).
Abatacept was generally well tolerated up to a
maximum exposure of 7 years, with no new safety signals
and comparable safety between the 3 treatment groups
(double-blind abatacept, double-blind placebo, and initial
nonresponders). The IRs for AEs, SAEs, infections, seri-
ous infections, malignancies, and autoimmune events did
not increase with continued exposure to abatacept during
the LTE phase relative to the short-term phase (combined
lead-in and double-blind periods). Furthermore, the num-
ber of patients with reported immunogenic antibody
responses did not increase during the LTE phase, and the
presence of anti-abatacept antibodies was not associated
with any significant loss of efficacy or with safety concerns.
Abatacept was associated with clinical efficacy im-
provements as assessed using ACR Pedi responses during
the initial 4-month lead-in phase; these improvements
were maintained over time with continued treatment.
Patients who had been randomized to the double-blind
placebo group during the withdrawal period had lower
ACR Pedi responses at the start of the LTE phase com-
pared with patients who had been randomized to the
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double-blind abatacept group. By month 6 of the LTE
phase, however, the mean ACR Pedi responses increased
and were comparable with those observed in the double-
blind abatacept group. Furthermore, continued use of aba-
tacept in patients who did not achieve an ACR Pedi 30
response within the first 4 months of treatment resulted in
improved responses over time in some patients.
An objective of this long-term analysis was to
evaluate the maintenance of clinical efficacy with conti-
nued treatment. Given that a large proportion of the
study population discontinued participation during the
course of the LTE phase, 2 analysis methods were used
to address this shortcoming. An as-observed analysis
was used to evaluate disease activity in patients who
continued to receive abatacept. Of the 153 patients who
entered the LTE phase, 69 (45%) remained in the study
until the end; of the 84 patients who discontinued, 24
did so due to loss of efficacy of the study drug.
Currently, there is discussion in the rheumatology
community regarding the best way to present long-term
followup efficacy data such as these, although no con-
sensus or recommendations have yet been published (28).
Therefore, we also performed an analysis of ACR Pedi
responses in the ITT population, with nonresponder
imputation. In this analysis, the proportions of patients
achieving an ACR Pedi 90 response or clinically inactive
disease status remained relatively stable during the LTE
phase (21–27% and 16–22%, respectively). The propor-
tions of patients determined to be demonstrating ACR
Pedi 30 and Pedi 50 responses declined over time, which
is likely reflective of patients discontinuing treatment.
This represents a conservative assessment, because .50%
of discontinuing patients stopped treatment because of
reasons other than lack of efficacy or AEs. However, it
should be noted that the discontinuation rate for abata-
cept, with 69 (36.3%) of 190 patients still receiving treat-
ment at the last available followup visit (year 7), was
similar to the rates for other biologic agents such as inflixi-
mab (36 [29.5%] of 122 patients at year 4) (27) and eta-
nercept (26 [44.8%] of 58 patients at year 8) (26).
Patient-reported end points allow us to evaluate
tangible outcomes that may be more meaningful to
patients in terms of their overall physical and psycholo-
gical health. Such outcomes are recognized as a valuable
addition to traditional clinical efficacy outcomes, and
together they can provide an overall picture of how a
treatment is affecting multiple aspects of a disease and
associated QOL. Progressive improvements in the CHQ
score were seen throughout the study for patients who
continued to receive treatment, with these patients
achieving mean scores that were comparable with those
for healthy children. Improvements in CHQ summary
scores that were gained after the initial short-term treat-
ment were also maintained with continued long-term
therapy and were generally within the range for healthy
children. Patients in all treatment groups experienced
reductions in pain and improvement in sleep quality
that were maintained with continued treatment.
Improvements in activity participation were also main-
tained with continued treatment and translated into
meaningful reductions in the number of days of activity
missed by parents and/or caregivers and the number of
school days missed per month.
Long-term followup data for the treatment of JIA
with other available biologic therapies are scarce, with
the exception of etanercept, for which clinical efficacy
and safety have been demonstrated for up to 8 years (26).
Sustained clinical efficacy was reported for patients con-
tinuing to receive etanercept treatment, with 26 (44.8%)
of 58 LTE-treated patients remaining in the study at final
followup, and the safety profile was similar to that ob-
served in patients with rheumatoid arthritis. Indirect
comparisons of data from randomized clinical trials in
JIA suggest that there are no significant differences in
the short-term efficacy of etanercept, adalimumab, and
abatacept (29). No direct comparisons are available for
the long-term efficacy and safety of biologic therapies for
the treatment of JIA. However, the maintained improve-
ments in disease activity with long-term abatacept treat-
ment reported here appear to be consistent with
observations for etanercept, suggesting that abatacept is
a clinically efficacious alternative option that is also well
tolerated and confers high patient acceptance.
These data show that long-term treatment with
abatacept for up to 7 years is associated with consistent
safety relative to the short-term period and, in patients
continuing treatment, sustained efficacy and tangible
QOL benefits, demonstrating that abatacept is a well-
tolerated and viable treatment for patients with JIA.
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